MAP3K14 and classic Hodgkin lymphoma: Both have been reported as mutated in human classical Hodgkin lymphoma (Otto et al. 2012) as well as mantle cell lymphoma, where MAP3K14 was recently reported as a new therapeutic target (Rahal et al. 2014).